SCHEMBL1050169

SCHEMBL1050169

C#CCCCCCCCCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 1.00
▸ CYP1A2 P05177 1/20 1.00
▸ CYP2D6 P10635 1/20 1.00
▸ MAPT P10636 1/20 1.00
▸ CYP2C9 P11712 1/20 1.00
▸ CYP2C19 P33261 1/20 1.00
▸ TSHR P16473 4/20 0.60
▸ LMNA P02545 2/20 0.60
▸ NFKB1 P19838 1/20 0.60
▸ PMP22 Q01453 1/20 0.60
▸ PTPN7 P35236 3/20 0.54
▸ HMGCR P04035 3/20 0.54
▸ GPR84 Q9NQS5 3/20 0.50
▸ FFAR1 O14842 1/20 0.50
▸ FFAR4 Q5NUL3 1/20 0.50
▸ PPARG P37231 3/20 0.48
▸ PPARD Q03181 3/20 0.48
▸ PPARA Q07869 3/20 0.48
▸ HDAC11 Q96DB2 2/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20293445 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL740489 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL2803510 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL12680242 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL40510 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL2802414 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL257132 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL2985078 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL979048 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9
SCHEMBL29377936 1.00 HSD17B10 (1.00) HSD17B10CYP1A2CYP2D6MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120136965-A Isolated polypeptide of targeted MPP8 protein and application thereof 苏州系统医学研究所 2025-06-13 — — CN claimed
EP-0450742-B1 DTPA-Monoamids, pharmaceutical compositions containing them, their use and process for their preparation SCHERING AG (DE) 1994-07-06 — — EP claimed
EP-3893934-B1 INSULIN CONJUGATES SANOFI SA (FR) 2025-09-10 — — EP disclosed
CN-120136965-A Isolated polypeptide of targeted MPP8 protein and application thereof 苏州系统医学研究所 2025-06-13 — — CN disclosed
EP-4520348-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF Sunforest (Beijing) Biopharma Ltd (CN) 2025-03-12 — — EP disclosed
WO-2023213310-A9 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2025-02-20 — — WO disclosed
US-12097261-B2 CDK2 degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-24 — — US disclosed
CN-117715904-A CDK2 degrading agents and uses thereof 凯麦拉医疗公司 2024-03-15 — — CN disclosed
EP-4334307-A1 CDK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
WO-2023213310-A1 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2023-11-09 — — WO disclosed
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-13 — — US disclosed
WO-2011134538-A1 DIYNE COMPOSITIONS EVOLVA LTD (CH) 2011-11-03 — — WO disclosed
EP-2376432-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2011-10-19 — — EP disclosed
WO-2011006061-A1 DIYNE COMPOSITIONS EVOLVA SA (CH) 2011-01-13 — — WO disclosed
WO-2010081683-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (DE) 2010-07-22 — — WO disclosed
WO-2010081683-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (DE) 2010-07-22 — — WO disclosed
EP-2208720-A1 Novel eicosanoid derivatives Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2010-07-21 — — EP disclosed
EP-2208720-A1 Novel eicosanoid derivatives Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2010-07-21 — — EP disclosed
EP-1021551-A1 PLANT FATTY ACID HYDROXYLASE GENES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2000-07-26 — — EP disclosed
WO-1999018224-A1 PLANT FATTY ACID HYDROXYLASE GENES THE CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (US) 1999-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12097261-B2 CDK2 degraders and uses thereof CDK2, CDK20, CDK1 HSD17B10 2743/4885CYP1A2 2027/4885CYP2D6 973/4885
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 HSD17B10 2743/4885CYP1A2 2027/4885CYP2D6 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback